Past Events | Evaxion Biotech

Key opinion leader and the trial’s principal investigator, Professor Georgina V. Long, will present the data from the one-year interim analysis and discuss challenges in the medical treatment of advanced melanoma. In the end, a Q&A session will be held, and participants are encouraged to present questions.

Professor Georgina Long AO, BSc (Hons1, UM) PhD MBBS (Hons) FRACP FAHMS AAHMS FAA, is Co-Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney. She leads an extensive clinical trials team and laboratory at MIA, with a focus on targeted therapies and immuno-oncology in melanoma. She is principal investigator on phase I, II and III clinical trials in adjuvant and metastatic melanoma, including trials in patients with active brain metastases. She is the chief investigator on NHMRC funded research into the molecular biology of melanoma, with a particular interest in clinical and tissue biomarker correlates of systemic therapy sensitivity and resistance. In recognition of her ground-breaking research and work, Professor Long was named 2024 Australian of the Year and was awarded Fellowship with the Australian Academy of Science (2024), recognized with the Australian Academy of Health and Medical Sciences Outstanding Female Research Medal 2021 and was appointed as an Officer of the Order of Australia (2020) and has received numerous awards, including ESMO Fulbright U.S. Mission Australia Award for Leadership Excellence (2024), Women for Oncology Award (2023), Sydney Local Health District/Sydney Research 2022 Research Excellence Award (2022) the prestigious Ramaciotti Medal for Biomedical Research (2021), Vice Chancellor’s Award for Excellence Award for Outstanding Research (2021), University of Sydney (2021), Research Australia GSK Research Excellence Award (2018) and the Sir Zelman Cowen Universities Fund Prize for Discovery in Medical Research (2016). She has a number of CINSW Premiers Awards, including; the Outstanding Cancer Researcher (2018), the Excellence in Translational Cancer Research Award (2017), the Wildfire Award for the most highly-cited, original, peer-reviewed article published (2011, 2014, 2016, 2017, 2018, 2019 & 2020), and in 2013 she was named the Outstanding Cancer Research Fellow. She is also Clarivate highly-cited Researcher for 2017-2022. Her H index is 140 and in August 2024 she was ranked the world’s equal 1st melanoma expert in all fields and discipline (http://expertscape.com/ex/melanoma) Professor Long is the author of over 500 peer-reviewed publications in clinical and translational research in melanoma, including the New England Journal of Medicine, Lancet, Lancet Oncology, Science, Nature, Journal of Clinical Oncology and Cancer Discovery. Professor Long has presented her work at international conferences and meetings on more than 250 occasions. She is Past President for the prestigious international Society for Melanoma Research (President 2018-2020), is a member and Chair of the ASCO (2015-2017) and ESMO (2017-2020) Scientific Committee for Melanoma/Skin cancer, is medical oncology lead for the Australian Melanoma Management Guidelines Committee, and is member of both the ASCO Plenary Series and ASCO AGM Education committees (2021-2024) she is on the editorial boards of several high-impact journals, and is a member of the Melanoma Expert Panel for AJCC Cancer Staging System 8th edition.

Professor Long was awarded the University Medal in Organic Chemistry. She subsequently completed her PhD in Chemistry in the field of anti-cancer agents and their binding to DNA. She then moved to the USA to take up a Fulbright Postdoctoral Fellowship at Scripps Research Institute, exploring nanotechnology in cancer treatment, before returning to Australia to complete her MBBS (Hons). Professor Long became a Fellow of the Australasian College of Physicians in January 2008, specialising in medical oncology.

Every year, 375+ thought leaders and influencers from industry and academia converge to showcase the latest breakthroughs in cancer immunology. Beyond the enriching discussions, the dynamic venue fosters extensive networking and collaborative opportunities, empowering teams to focus on their objectives.This summit offers a comprehensive 3-day 6-track program, exploring bi- and multispecific biotherapeutics; highlighting the latest developments in CAR T therapies, emerging targeting technologies, personalized immunotherapy, and cell-based immunotherapies; and addressing the challenges of overcoming tumor resistance.

Thomas Trolle, Evaxion's Director of Bioinformatics & AI/ML, will present on August 7 at 8:05 AM EST, discussing computational methods for identifying targetable antigens in personalized cancer immunotherapies.

Click here to learn more about the conference

The International Conference on Intelligent Systems for Molecular Biology (ISMB) is an annual event organized by the International Society for Computational Biology (ISCB). This flagship meeting of the ISCB is renowned as the world's largest conference focused on bioinformatics and computational biology. ISMB 2024 showcases the latest international developments in the field and driving forward the future of this dynamic area of research and the involvement of the ISCB's Communities of Special Interest (COSIs) enhances the exceptional scientific program.

Click here to learn more about the conference

iAccess Alpha hosts virtual investor conferences, where presenting companies are recommended by a network of investors. The conference format spans two days, with company webcast presentations on day one, followed by one-on-one meetings with company management teams on day two. To learn more about the iAccess Alpha Buyside Best Ideas Summer Conference 2024 on June 25 and 26, 2024 or to register and schedule a one-on-one meeting with Evaxion, please visit the conference website https://www.iaccessalpha.com/home

This R&D Day will feature a series of talks from Evaxion’s scientists and bioinformaticians, providing insights into Evaxion’s validated AI-Immunology™ platform for vaccine target discovery, design and development. The different talks will be followed by Q&A sessions for participants to interact.

The event will highlight the unique predictive capabilities that differentiate the AI-Immunology™ platform and how these can help address severe unmet medical needs for patients with cancer and infectious diseases.

The agenda of the event will be available closer to the R&D Day.

The mRNA Cancer Vaccine Summit 2023 comes to Boston as the community is on the cusp of something truly exciting. This is the first and only forum dedicated to showcasing mRNA cancer vaccine technology advances, translational insights and critical clinical updates from the global leaders working towards effective harnessing of neoantigens and developing successful tailor-made mRNA cancer vaccines. Unite with mRNA cancer vaccine, oncology and immune-oncology leaders and stay up to date about these innovative cancer therapies. With individualized neoantigen therapies showing critical promise in the clinic, neoantigen leaders unite to exhibit a whole-day dedicated to neoantigen discovery and identification, towards optimized discovery and development of personalized cancer vaccines to differentiate and fast track your pipelines.

Click here to learn more about the conference.

The 23rd International Pathogenic Neisseria Conference aims to bring together passionate scientists, emerging and experienced researchers and clinicians from all continents to discuss the clinical presentation, epidemiology, population genomics, vaccine research and development, host-pathogen interactions and gene regulation of these Neisseria species in order to keep abreast of the latest developments in this field. IPNC is a great opportunity for networking and forming collaborations for future work on pathogenic Neisseria species.

Click here to learn more about the conference.

The R&D Day will feature a series of talks from Evaxion scientists and collaborators, sharing previously unreleased preclinical data highlighting the use of Evaxion’s proprietary genetic immune adjuvant (Antigen Presenting Cell targeting) technology. This technology has been shown to enhance vaccination effects for both DNA and mRNA vaccines across a range of therapeutic vaccine applications.

The event will be hosted with the possibility of physical attendance at Evaxion’s facilities in Hørsholm, Denmark and as a live webcast.

Please write to info@evaxion-biotech.com with the following details to sign up for the physical attendance for R&D day:

Subject: R&D Day

Message: Your full name

Please join us on Tuesday, April 12th at 12:30 PM EDT for a webinar featuring Key Opinion Leaders Jeffrey S. Weber MD, PhD (NYU-Grossman School of Medicine) and Patrick Ott, MD, PhD (Dana Farber Cancer Institute). Dr. Weber will discuss the current treatment landscape and unmet medical needs in patients with metastatic melanoma. Dr. Ott will discuss the novel neoepitope-targeting approach to improving the treatment for patients suffering from metastatic melanoma. A live Q&A session will follow the discussion.

Alert type
Event
News

Subscribe to Investor Email Alerts